STAb Therapeutics, spin-off from Instituto de Investigación Hospital 12 de Octubre i+12, has been awarded by the Fundación para el Conocimiento Madri+d, in the framework of the health entrepreneurship program ‘Healthstart’. This award is a recognition to the company´s viability plan, developed by scientists from this institution, to transfer the results obtained in their laboratory to the clinic. The Immuno-Oncology and Immunotherapy group, led by Dr Luis Álvarez-Vallina, has developed a new cancer immunotherapy for B-cell leukemias and lymphomas and has received funding by Instituto de Salud Carlos III to perform a First in Human phase I clinical trial. The spin-off company has been launched to conduct further clinical development of this therapy and the award will contribute to this goal. The ‘STAb-T19 Immunotherapy Project’ was selected among all the participants to receive one of the 5 first prizes, which were collected by Dr Belén Blanco and Dr Anaïs Jiménez, who have participated in the Healthstart programme. In addition, the participants have received training in entrepreneurship and fundraising processes.
